https://orcid.org/0000-0002-8291-6164
References
- Rollig C, Knop S, Bornhauser M. Multiple myeloma. Lancet. 2015;385(9983):2197–2208.
- Kunacheewa C, Orlowski RZ. New drugs in multiple myeloma. Annu Rev Med. 2019;70:521–547.
- Kumar SK, Rajkumar V, Kyle RA, et al. Multiple myeloma. Nat Rev Dis Primers. 2017;3:17046.
- Paiva B, van Dongen JJ, Orfao A. New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood. 2015;125(20):3059–3068.
- Rajkumar SV, Kumar S. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc. 2016;91(1):101–119.
- Aguilo F, Di Cecilia S, Walsh MJ. Long non-coding RNA ANRIL and polycomb in human cancers and cardiovascular disease. Curr Top Microbiol Immunol. 2016;394:29–39.
- Poi MJ, Li J, Sborov DW, et al. Polymorphism in ANRIL is associated with relapse in patients with multiple myeloma after autologous stem cell transplant. Mol Carcinog. 2017;56(7):1722–1732.
- Sun LY, Li XJ, Sun YM, et al. LncRNA ANRIL regulates AML development through modulating the glucose metabolism pathway of AdipoR1/AMPK/SIRT1. Mol Cancer. 2018;17(1):127.
- Wang CH, Li QY, Nie L, et al. LncRNA ANRIL promotes cell proliferation, migration and invasion during acute myeloid leukemia pathogenesis via negatively regulating miR-34a. Int J Biochem Cell Biol. 2020;119:105666.
- Pennucci V, Zini R, Norfo R, et al. Abnormal expression patterns of WT1-as, MEG3 and ANRIL long non-coding RNAs in CD34+ cells from patients with primary myelofibrosis and their clinical correlations. Leuk Lymphoma. 2015;56(2):492–496.
- Zhang LM, Ju HY, Wu YT, et al. Long non-coding RNA ANRIL promotes tumorgenesis through regulation of FGFR1 expression by sponging miR-125a-3p in head and neck squamous cell carcinoma. Am J Cancer Res. 2018;8(11):2296–2310.
- Zhang JJ, Wang DD, Du CX, et al. Long noncoding RNA ANRIL promotes cervical cancer development by acting as a sponge of miR-186. Oncol Res. 2018;26(3):345–352.
- Wu L, Zhang C, Chu M, et al. miR-125a suppresses malignancy of multiple myeloma by reducing the deubiquitinase USP5. J Cell Biochem. 2020;121(1):642–650.
- Liu Z, Zhang G, Yu W, et al. miR-186 inhibits cell proliferation in multiple myeloma by repressing Jagged1. Biochem Biophys Res Commun. 2016;469(3):692–697.
- Wu S, He X, Li M, et al. MiRNA-34a overexpression inhibits multiple myeloma cancer stem cell growth in mice by suppressing TGIF2. Am J Transl Res. 2016;8(12):5433–5443.
- Rajkumar SV, Dimopoulos MA, Palumbo A, et al. 2014 International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Nihon Rinsho. 2016;74(Suppl 5):264–268.
- Tianhua Y, Dianqiu L, Xuanhe Z, et al. Long non-coding RNA Sox2 overlapping transcript (SOX2OT) promotes multiple myeloma progression via microRNA-143-3p/c-MET axis. J Cell Mol Med. 2020;24(9):5185–5194.
- Wang M, Zhao HY, Zhang JL, et al. Dysregulation of LncRNA ANRIL mediated by miR-411-3p inhibits the malignant proliferation and tumor stem cell like property of multiple myeloma via hypoxia-inducible factor 1alpha. Exp Cell Res. 2020;396(1):112280.
- Yang N, Chen J, Zhang H, et al. LncRNA OIP5-AS1 loss-induced microRNA-410 accumulation regulates cell proliferation and apoptosis by targeting KLF10 via activating PTEN/PI3K/AKT pathway in multiple myeloma. Cell Death Dis. 2017;8(8):e2975.
- Xu J, Su Y, Xu A, et al. miR-221/222-Mediated inhibition of autophagy promotes dexamethasone resistance in multiple myeloma. Mol Ther. 2019;27(3):559–570.
- Cao Y, Shi X, Liu Y, et al. MicroRNA-338-3p inhibits proliferation and promotes apoptosis of multiple myeloma cells through targeting cyclin-dependent kinase 4. Oncol Res. 2018;27(1):117–124.
- Anderson KC, Alsina M, Atanackovic D, et al. Multiple myeloma, Version 2.2016: clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2015;13(11):1398–1435.
- Xiao X, Gu Y, Wang G, et al. c-Myc, RMRP, and miR-34a-5p form a positive-feedback loop to regulate cell proliferation and apoptosis in multiple myeloma. Int J Biol Macromol. 2019;122:526–537.